Literature DB >> 6489768

Daunomycin in the treatment of experimental proliferative vitreoretinopathy: retinal toxicity of intravitreal daunomycin in the rabbit.

M Santana, P Wiedemann, M Kirmani, D S Minckler, R Patterson, N Sorgente, S J Ryan.   

Abstract

The retinal toxicity of daunomycin, a drug that effectively suppresses experimental proliferative vitreoretinopathy (PVR), was studied in the rabbit by clinical examination, electroretinography (ERG), light microscopy, and electron microscopy. Although no toxicity was observed at the therapeutically effective dose of 10 nmol per eye, the safety margin is too small to recommend this drug for therapy of proliferative vitreoretinopathy in man.

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6489768     DOI： 10.1007/bf02134142

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN： 0721-832X            Impact factor:   3.117


  8 in total

1.  Massive periretinal proliferation: a logical approach to therapy.

Authors:  R Machemer
Journal:  Trans Am Ophthalmol Soc       Date:  1977

2.  Control of experimental massive periretinal proliferation by daunomycin: dose-response relation.

Authors:  P Wiedemann; M Kirmani; M Santana; N Sorgente; S J Ryan
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1983       Impact factor: 3.117

Review 3.  Toxicology of daunorubicin in animals and man.

Authors:  R J Maral; M Jouanne
Journal:  Cancer Treat Rep       Date:  1981

4.  Experimental double-perforating injury of the posterior segment in rabbit eyes: the natural history of intraocular proliferation.

Authors:  T M Topping; G W Abrams; R Machemer
Journal:  Arch Ophthalmol       Date:  1979-04

5.  The effect of penicillamine on posttraumatic vitreous proliferation.

Authors:  J F Weiss; M Belkin
Journal:  Am J Ophthalmol       Date:  1981-11       Impact factor: 5.258

6.  Experimental Fibroplasia in the rabbit vitreous. Retinal detachment induced by autologous fibroblasts.

Authors:  P Algvere; E Kock
Journal:  Albrecht Von Graefes Arch Klin Exp Ophthalmol       Date:  1976-05-26

7.  Treatment of intraocular proliferations with intravitreal steroids.

Authors:  R Machemer; G Sugita; Y Tano
Journal:  Trans Am Ophthalmol Soc       Date:  1979

8.  Fluorouracil for the treatment of massive periretinal proliferation.

Authors:  M S Blumenkranz; A Ophir; A J Claflin; A Hajek
Journal:  Am J Ophthalmol       Date:  1982-10       Impact factor: 5.258
  8 in total
  20 in total

1.  Evaluation of radiation therapy for experimental proliferative vitreoretinopathy in rabbits.

Authors:  S Kuriyama; T Ohuchi; N Yoshimura; Y Honda; M Hiraoka; M Abe
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1990       Impact factor: 3.117

2.  Porous silicon oxide-PLGA composite microspheres for sustained ocular delivery of daunorubicin.

Authors:  Kaihui Nan; Feiyan Ma; Huiyuan Hou; William R Freeman; Michael J Sailor; Lingyun Cheng
Journal:  Acta Biomater       Date:  2014-05-02       Impact factor: 8.947

3.  A Novel Approach of Daunorubicin Application on Formation of Proliferative Retinopathy Using a Porous Silicon Controlled Delivery System: Pharmacodynamics.

Authors:  Huiyuan Hou; Kristyn Huffman; Sandy Rios; William R Freeman; Michael J Sailor; Lingyun Cheng
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-04       Impact factor: 4.799

4.  Cytotoxic effects of antiproliferative agents on human retinal glial cells in vitro.

Authors:  J Cai; R Wei; X Ma; H Zhu; Y Li
Journal:  Int Ophthalmol       Date:  2001       Impact factor: 2.031

5.  Oxidized porous silicon particles covalently grafted with daunorubicin as a sustained intraocular drug delivery system.

Authors:  Jay Chhablani; Alejandra Nieto; Huiyuan Hou; Elizabeth C Wu; William R Freeman; Michael J Sailor; Lingyun Cheng
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-02-01       Impact factor: 4.799

6.  Measurement of cellular proliferation within the vitreous during experimental proliferative vitreoretinopathy.

Authors:  C M Yang; K R Olsen; E Hernandez; S W Cousins
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1992       Impact factor: 3.117

7.  Daunorubicin treatment in a refined experimental model of proliferative vitreoretinopathy.

Authors:  J A Khawly; P Saloupis; D L Hatchell; R Machemer
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1991       Impact factor: 3.117

8.  Growth inhibition of human Tenon's capsule fibroblasts and rabbit dermal fibroblasts with non-carcinogenic N-alkylated anthracyclines.

Authors:  U H Steinhorst; E P Chen; S F Freedman; R Machemer; D L Hatchell
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1994-06       Impact factor: 3.117

9.  Corticosteroids and daunomycin in the prevention of experimental proliferative vitreoretinopathy induced by macrophages.

Authors:  Y N Hui; H C Liang; Y S Cai; B Kirchhof; K Heimann
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1993-02       Impact factor: 3.117

10.  Ocular toxicity of daunomycin: effects of subdivided doses on the rabbit retina after vitreous gas compression.

Authors:  U H Steinhorst; D L Hatchell; E P Chen; R Machemer
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1993-10       Impact factor: 3.117
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.